Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate

Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate

Abstract Evaluation of treatment response is among the major challenges in modern oncology. We herein used a monoclonal antibody targeting the EGF receptor (EGFR) labelled with the alpha emitter 213Bi (213Bi-anti-EGFR-MAb). EJ28Luc (bladder) and LN18 (glioma) cancer cells, both overexpressing EGFR,...

Full description

Bibliographic Details
Main Authors: Benedikt Feuerecker, Philipp Biechl, Christof Seidl, Frank Bruchertseifer, Alfred Morgenstern, Markus Schwaiger, Wolfgang Eisenreich
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84421-4

Internet

https://doi.org/10.1038/s41598-021-84421-4

Similar Items